JulieMPaikMD

Nephrology • Boston, MA

Physician

Join to view full profile

Dr. Paik is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Paik's full profile

Already have an account?

Office
Brigham Womens Hospital
75 Francis St Renal Div MRB4
Boston, MA 02115
Phone+1 617-732-6383

Education & Training

Brigham and Women's Hospital/Massachusetts General HospitalFellowship, Nephrology, 2007 - 2011
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2004 - 2007
Icahn School of Medicine at Mount SinaiClass of 2004

Certifications & Licensure

MA State Medical License 2007 - 2025
NY State Medical License 2005 - 2007

Publications & Presentations

PubMed

Evidence on the benefits of statins for CVD prevention in older adults with CKD.
Ariela R Orkaby, Julie M Paik
The Lancet. Healthy Longevity. 2025-03-04
Comparative Effectiveness of Individual Sodium-Glucose Cotransporter 2 Inhibitors.
HoJin Shin, Julie M Paik, Brendan M Everett, Elyse DiCesare, Caroline Alix
JAMA Internal Medicine. 2025-03-01
Empagliflozin versus DPP4i or GLP-1RA for the risk of nephrolithiasis in patients with type 2 diabetes: Research letter from the EMPRISE cohort study.
Helen Tesfaye, Julie M Paik, Heidi Zakoul, Niklas Schmedt, Deborah J Wexler
Diabetes, Obesity & Metabolism. 2025-02-28

Press Mentions

SGLT2 Inhibitors vs DPP4 Inhibitors Lower Hyperkalemia Risk in CKD+T2D CasesAugust 15th, 2024
Empagliflozin May Reduce Stone RiskNovember 5th, 2022
SGLT2 Inhibitor Use Rising in Patients with DKDAugust 23rd, 2021
Join now to see all